Real-World Evidence Studies in Chinese Regulatory Submissions
Real-World Evidence Studies in Chinese Regulatory Submissions The Role of Real-World Evidence in Regulatory Submissions in China Introduction Real-world evidence (RWE) has become an increasingly important component of drug development and regulatory decision-making globally. In China, the National Medical Products Administration (NMPA) has embraced RWE as part of its strategy to accelerate drug access and…
Read More “Real-World Evidence Studies in Chinese Regulatory Submissions” »